← 返回

伴 UNC13D 和 CD27 胚系突变的复发/难治性外周 T 细胞淋巴瘤相关噬血细胞性淋巴组织细胞增生症

英文原题:Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.

查看英文原题

Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations.

PubMed 2024/01/01(内容时间) Cell Transplant Q2 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

噬血细胞性淋巴组织细胞增多症(HLH)是一种严重的高炎症性疾病,可分为家族性和获得性。本研究报告一名26岁男性患者,患有复发/难治性外周T细胞淋巴瘤并发HLH。全外显子测序发现与HLH相关的胚系突变,包括CD27和UNC13D等关键基因,以及其他杂合胚系变异(NOTCH2、NOTCH3、IL2RA、TYK2、AGL、CFD和F13A1)。CD107a分析持续显示细胞毒性T淋巴细胞和自然杀伤(NK)细胞脱颗粒受损。家系调查发现患者父亲和母亲分别携带UNC13D和CD27突变,兄弟也携带相同的CD27杂合突变,但均未发病。尽管CD27错义变异(c.779C>T;p.Pro260Leu)此前未在数据库中记录,综合分析提示该变异无致病性,对T细胞和NK细胞功能影响很小。上述结果支持将造血干细胞移植(HSCT)作为成功的根治性治疗方案。截至报告时,患者在HSCT后15.2个月仍无淋巴瘤,HLH保持静止。

本研究强调,基因检测有助于识别重要突变并确认其病因,为尽早制定治疗方案及选择合适移植供者提供依据。

展开英文摘要原文

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory disease characterized by familial and acquired forms.

Here, we present the case of a 26-year-old male patient with relapsed/refractory peripheral T-cell lymphoma and concurrent HLH. Whole-exon sequencing revealed germline mutations associated with HLH, including those in critical genes such as CD27 and UNC13D and other germline heterozygous variants ( NOTCH2, NOTCH3, IL2RA, TYK2, AGL, CFD , and F13A1 ).

CD107a analyses consistently demonstrated impaired degranulation of cytotoxic T-lymphocytes and natural killer (NK) cells. Examination of the patient's family pedigree revealed that his father and mother harbored UNC13D and CD27 mutations, respectively; his brother carried the same CD27 heterozygous mutation.

However, none of them manifested the disease. Despite the missense mutation of CD27 (c. 779C>T; p. Pro260Leu) lacking previous documentation in databases, comprehensive analysis suggested non-pathogenic mutations in the CD27 variant, indicating minimal impact on T- and NK-cell functions. These results ultimately supported the option of hematopoietic stem cell transplantation (HSCT) as a successful curative therapeutic approach. As of this report, the patient has remained free of lymphoma and quiescent HLH 15. 2 months post-HSCT.

This study underscores the efficacy of genetic tests in identifying significant mutations and confirming their etiologies, providing an early basis for treatment decisions and the selection of suitable transplant donors.

论文信息

作者
Yang T、Chen R、Zhang M、Jing R、Geng J、Wei G、Luo Y、Xiao P
单位
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.China
文献类型
病例报告 · 非美国政府资助研究
期刊
Cell transplantation2024 Jan-Dec
原文标识
PubMed 38183241 · DOI 10.1177/09636897231221887